1. Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of
medicine. 1971;285:1182-6.
2. Hanahan D and Folkman J. Patterns and Emerging Mechanisms of the Angiogenic Switch
during Tumorigenesis. Cell. 1996;86:353-364.
3. A.G. Ide NHB, S.L. Warren. Vascularization of the Brown Pearce rabbit epithelioma
transplant as seen in the transparent ear chamber. Am J Roentgenol. 1939;42:891-899.
4. Folkman J, Merler E, Abernathy C and Williams G. Isolation of a tumor factor
responsible for angiogenesis. The Journal of experimental medicine. 1971;133:275-88.
5. Ellis LM. Mechanisms of Action of Bevacizumab as a Component of Therapy for
Metastatic Colorectal Cancer. Seminars in Oncology. 2006;33:S1-S7.
6. Ferrara N, Hillan KJ, Gerber HP and Novotny W. Discovery and development of
bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery.
2004;3:391-400.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J,
Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The New England journal of medicine. 2004;350:2335-42.
41
8. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M and
Ferrara N. Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal
Antibody for the Therapy of Solid Tumors and Other Disorders. Cancer Research.
1997;57:4593-4599.
9. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Experimental cell research. 2006;312:594-607.
10. Wu YS, Shui L, Shen D and Chen X. Bevacizumab combined with chemotherapy for
ovarian cancer: an updated systematic review and meta-analysis of randomized controlled
trials. Oncotarget. 2017;8:10703-10713.
11. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature reviews
Drug discovery. 2007;6:273-86.
12. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F,
Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL and
Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo
in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia
Group B (CALGB 80303). Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2010;28:3617-22.
13. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh
G, Hollister B, Rosen O and Plowman GD. Effects of anti-VEGF treatment duration on
42
tumor growth, tumor regrowth, and treatment efficacy. Clinical cancer research : an
official journal of the American Association for Cancer Research. 2010;16:3887-900.
14. Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S,
Tanaka Y, Sakata M, Burger RA, Kimura T and Ohmichi M. Maintenance treatment with
bevacizumab prolongs survival in an in vivo ovarian cancer model. Clinical cancer
research : an official journal of the American Association for Cancer Research.
2008;14:7781-9.
15. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N. Inhibition of
vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature. 1993;362:841-4.
16. Weidner N, Semple JP, Welch WR and Folkman J. Tumor Angiogenesis and Metastasis
— Correlation in Invasive Breast Carcinoma. New England Journal of Medicine.
1991;324:1-8.
17. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and
Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator
in early-stage breast carcinoma. Journal of the National Cancer Institute.
1992;84:1875-87.
18. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J. Tumor angiogenesis
correlates with metastasis in invasive prostate carcinoma. The American journal of
43
pathology. 1993;143:401-409.
19. de la Taille A, Katz AE, Bagiella E, Buttyan R, Sharir S, Olsson CA, Burchardt T, Ennis
RD and Rubin MA. Microvessel density as a predictor of PSA recurrence after radical
prostatectomy. A comparison of CD34 and CD31. American journal of clinical pathology.
2000;113:555-62.
20. Yano T, Tanikawa S, Fujie T, Masutani M and Horie T. Vascular endothelial growth factor
expression and neovascularisation in non-small cell lung cancer. European journal of
cancer (Oxford, England : 1990). 2000;36:601-9.
21. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N,
Inui K and Wada H. Evaluation of angiogenesis in non-small cell lung cancer:
comparison between anti-CD34 antibody and anti-CD105 antibody. Clinical cancer
research : an official journal of the American Association for Cancer Research.
2001;7:3410-5.
22. Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K and Sugimachi K. High
vascularity in the peripheral region of non-small cell lung cancer tissue is associated with
tumor progression. Lung cancer (Amsterdam, Netherlands). 2001;34:233-41.
23. Cesca M, Morosi L, Berndt A, Nerini IF, Frapolli R, Richter P, Decio A, Dirsch O,
Micotti E, Giordano S, D'Incalci M, Davoli E, Zucchetti M and Giavazzi R.
Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous
44
Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. Molecular
Cancer Therapeutics. 2016;15:125-135.
24. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL,
McCarville MB, Stewart CF and Davidoff AM. Bevacizumab-induced transient
remodeling of the vasculature in neuroblastoma xenografts results in improved delivery
and efficacy of systemically administered chemotherapy. Clinical cancer research : an
official journal of the American Association for Cancer Research. 2007;13:3942-50.
25. Ehling J, Theek B, Gremse F, Baetke S, Mockel D, Maynard J, Ricketts SA, Grull H,
Neeman M, Knuechel R, Lederle W, Kiessling F and Lammers T. Micro-CT imaging of
tumor angiogenesis: quantitative measures describing micromorphology and
vascularization. The American journal of pathology. 2014;184:431-41.
26. Gyanchandani R, Ortega Alves MV, Myers JN and Kim S. A Proangiogenic Signature Is
Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell
Carcinoma. Molecular Cancer Research. 2013;11:1585-1596.
27. Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K,
Yamamoto Y, Murayama Y, Tamiya T, Yoshida K and Sasaki H. Histopathological
investigation of glioblastomas resected under bevacizumab treatment. Oncotarget.
2016;7:52423-52435.
28. Zhao YY, Xue C, Jiang W, Zhao HY, Huang Y, Feenstra K, Resau JH, Qian CN and
45
Zhang L. Predictive value of intratumoral microvascular density in patients with
advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab. Journal
of thoracic oncology : official publication of the International Association for the Study
of Lung Cancer. 2012;7:71-5.
29. Fidler IJ. Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis.
Cancer Research. 1978;38:2651-2660.
30. Jain RK and Stylianopoulos T. Delivering nanomedicine to solid tumors. Nature Reviews
Clinical Oncology. 2010;7:653-664.
31. McDonald DM and Choyke PL. Imaging of angiogenesis: from microscope to clinic.
Nature medicine. 2003;9:713-25.
32. Li X, Anton N, Zuber G and Vandamme T. Contrast agents for preclinical targeted X-ray
imaging. Advanced drug delivery reviews. 2014;76:116-133.
33. Hainfeld JF, Slatkin DN, Focella TM and Smilowitz HM. Gold nanoparticles: a new
X-ray contrast agent. The British journal of radiology. 2006;79:248-53.
34. Nebuloni L, Kuhn GA and Muller R. A comparative analysis of water-soluble and
blood-pool contrast agents for in vivo vascular imaging with micro-CT. Academic
radiology. 2013;20:1247-55.
35. Hubbell JH. Tables of X-ray mass attenuation coefficients and mass energy-absorption
coefficients. http://physicsnistgov/PhysRefData/XrayMassCoef/.
46
36. Majoros IJ, Keszler B, Woehler S, Bull T and Baker JR. Acetylation of Poly(amidoamine)
Dendrimers. Macromolecules. 2003;36:5526-5529.
37. Attia MF, Anton N, Chiper M, Akasov R, Anton H, Messaddeq N, Fournel S,
Klymchenko AS, Mely Y and Vandamme TF. Biodistribution of X-ray iodinated contrast
agent in nano-emulsions is controlled by the chemical nature of the oily core. ACS nano.
2014;8:10537-50.
38. Su X, Kuang L, Battle C, Shaner T, Mitchell BS, Fink MJ and Jayawickramarajah J. Mild
Two-Step Method to Construct DNA-Conjugated Silicon Nanoparticles: Scaffolds for the
Detection of MicroRNA-21. Bioconjugate Chemistry. 2014;25:1739-1743.
39. Chen Q, Wang H, Liu H, Wen S, Peng C, Shen M, Zhang G and Shi X. Multifunctional
Dendrimer-Entrapped Gold Nanoparticles Modified with RGD Peptide for Targeted
Computed Tomography/Magnetic Resonance Dual-Modal Imaging of Tumors. Analytical
Chemistry. 2015;87:3949-3956.
40. Cole LE, Vargo-Gogola T and Roeder RK. Contrast-Enhanced X-ray Detection of
Microcalcifications in Radiographically Dense Mammary Tissue Using Targeted Gold
Nanoparticles. ACS nano. 2015;9:8923-8932.
41. Yang X, Yang M, Pang B, Vara M and Xia Y. Gold Nanomaterials at Work in
Biomedicine. Chemical Reviews. 2015;115:10410-10488.
42. Al Zaki A, Joh D, Cheng Z, De Barros ALB, Kao G, Dorsey J and Tsourkas A.
47
Gold-Loaded Polymeric Micelles for Computed Tomography-Guided Radiation Therapy
Treatment and Radiosensitization. ACS nano. 2014;8:104-112.
43. Yang W, Ella-Menye J-R, Liu S, Bai T, Wang D, Yu Q, Li Y and Jiang S. Cross-Linked
Carboxybetaine SAMs Enable Nanoparticles with Remarkable Stability in Complex
Media. Langmuir. 2014;30:2522-2529.
44. Park G, Seo D, Chung IS and Song H. Poly(ethylene glycol)- and
Carboxylate-Functionalized Gold Nanoparticles Using Polymer Linkages: Single-Step
Synthesis, High Stability, and Plasmonic Detection of Proteins. Langmuir.
2013;29:13518-13526.
45. Yin Q, Yap FY, Yin L, Ma L, Zhou Q, Dobrucki LW, Fan TM, Gaba RC and Cheng J.
Poly(iohexol) nanoparticles as contrast agents for in vivo X-ray computed tomography
imaging. Journal of the American Chemical Society. 2013;135:13620-3.
46. Kim D, Park S, Lee JH, Jeong YY and Jon S. Antibiofouling Polymer-Coated Gold
Nanoparticles as a Contrast Agent for in Vivo X-ray Computed Tomography Imaging.
Journal of the American Chemical Society. 2007;129:7661-7665.
47. Liu H, Wang H, Xu Y, Guo R, Wen S, Huang Y, Liu W, Shen M, Zhao J, Zhang G and Shi
X. Lactobionic acid-modified dendrimer-entrapped gold nanoparticles for targeted
computed tomography imaging of human hepatocellular carcinoma. ACS applied
materials & interfaces. 2014;6:6944-53.
48
48. Kannan P, Kretzschmar WW, Winter H, Warren D, Bates R, Allen PD, Syed N, Irving B,
Papiez BW, Kaeppler J, Markelc B, Kinchesh P, Gilchrist S, Smart S, Schnabel JA,
Maughan T, Harris AL, Muschel RJ, Partridge M, Sharma RA and Kersemans V.
Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular
Morphology in Preclinical Tumors and in Human Liver Metastases. Clinical cancer
research : an official journal of the American Association for Cancer Research.
2018;24:4694-4704.
49. Nitta N, Takakusagi Y, Kokuryo D, Shibata S, Tomita A, Higashi T, Aoki I and Harada M.
Intratumoral evaluation of 3D microvasculature and nanoparticle distribution using a
gadolinium-dendron modified nano-liposomal contrast agent with magnetic resonance
micro-imaging. Nanomedicine : nanotechnology, biology, and medicine.
2018;14:1315-1324.
50. Savai R, Langheinrich AC, Schermuly RT, Pullamsetti SS, Dumitrascu R, Traupe H, Rau
WS, Seeger W, Grimminger F and Banat GA. Evaluation of angiogenesis using
micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia (New
York, NY). 2009;11:48-56.
51. Kiessling F, Greschus S, Lichy MP, Bock M, Fink C, Vosseler S, Moll J, Mueller MM,
Fusenig NE, Traupe H and Semmler W. Volumetric computed tomography (VCT): a new
technology for noninvasive, high-resolution monitoring of tumor angiogenesis. Nature
49
medicine. 2004;10:1133-8.
52. Zagorchev L, Oses P, Zhuang ZW, Moodie K, Mulligan-Kehoe MJ, Simons M and
Couffinhal T. Micro computed tomography for vascular exploration. Journal of
angiogenesis research. 2010;2:7.
53. Jørgen Fogh GT. New Human Tumor Cell Lines. Human Tumor Cells in Vitro.
1975:115-159.
54. Yunis AA, Arimura GK and Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in
continuous culture: sensitivity to asparaginase. International journal of cancer.
1977;19:128-35.
55. Huynh H, Teo CCM and Soo KC. Bevacizumab and rapamycin inhibit tumor growth in
peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics.
2007;6:2959-2966.
56. Arjaans M, Munnink THO, Oosting SF, van Scheltinga AGTT, Timmer-Bosscha H, de
Hooge MNL-, Schröder CP and de Vries EGE. Abstract 2438: Bevacizumab treatment
hampers tumor uptake of antibodies in human tumor bearing mice. Cancer Research.
2012;72:2438-2438.
57. Rein DT, Volkmer AK, Volkmer J, Beyer IM, Janni W, Fleisch MC, Welter AK,
Bauerschlag D, Schondorf T and Breidenbach M. Systemic administration of
bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian
50
cancer. Oncology letters. 2012;3:530-534.
58. Nakagawa T, Gonda K, Kamei T, Cong L, Hamada Y, Kitamura N, Tada H, Ishida T,
Aimiya T, Furusawa N, Nakano Y and Ohuchi N. X-ray computed tomography imaging
of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific
antibody via polyethylene glycol chains on their surface. Science and technology of
advanced materials. 2016;17:387-397.
59. Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V and
Tomao F. Bevacizumab in ovarian cancer: A critical review of phase III studies.
Oncotarget. 2017;8:12389-12405.
60. Uehara H. Angiogenesis of prostate cancer and antiangiogenic therapy. The journal of
medical investigation : JMI. 2003;50:146-153.
61. Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R,
Bicknell R and Harris AL. Expression of the Angiogenic Factors Vascular Endothelial
Cell Growth Factor, Acidic and Basic Fibroblast Growth Factor, Tumor Growth Factor β-1, Platelet-derived Endothelial Cell Growth Factor, Placenta Growth Factor, and Pleiotrophin in Human Primary Breast Cancer and Its Relation to Angiogenesis. Cancer
Research. 1997;57:963-969.
62. Vasudev NS and Reynolds AR. Anti-angiogenic therapy for cancer: current progress,
unresolved questions and future directions. Angiogenesis. 2014;17:471-94.
51
63. Bergers G and Song S. The role of pericytes in blood-vessel formation and maintenance.
Neuro-Oncology. 2005;7:452-464.
64. Benjamin LE, Golijanin D, Itin A, Pode D and Keshet E. Selective ablation of immature
blood vessels in established human tumors follows vascular endothelial growth factor
withdrawal. J Clin Invest. 1999;103:159-165.
65. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD,
Shalinsky DR, Thurston G, Yancopoulos GD and McDonald DM. Inhibition of Vascular
Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial
Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane
Ghosts. The American journal of pathology. 2004;165:35-52.
66. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B,
Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C,
Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L,
Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE,
Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J,
Iacobuzio-Donahue C, Griffiths J and Tuveson DA. Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New
York, NY). 2009;324:1457-61.
67. Nishihara H. Human pathological basis of blood vessels and stromal tissue for
52
nanotechnology. Advanced drug delivery reviews. 2014;74:19-27.
68. Hata A, Yanagawa M, Honda O, Kikuchi N, Miyata T, Tsukagoshi S, Uranishi A and
Tomiyama N. Effect of Matrix Size on the Image Quality of Ultra-high-resolution CT of
the Lung: Comparison of 512 x 512, 1024 x 1024, and 2048 x 2048. Academic radiology.
2018;25:869-876.
53